Urgent.News

What's breaking now, across thousands of outlets.

Finance & Markets

Russia stocks lower at close of trade; MOEX Russia Index unchanged

Russia stocks lower at close of trade; MOEX Russia Index unchanged

Russia stocks saw a decline after trading closed on Sunday, with the MOEX Russia Index remaining unchanged at 0.00%, marking a new three-month high. Surgutneftegas PJSC led the gains, surging 2.97% or 0.50 points to close at 17.34. NOVATEK PJSC also saw a rise, adding 2.96% or 33.40 points to finish at 1,161.40. Federal Hydro Generating Company RusHydro PJSC experienced a 2.93% increase or 0.01 points, closing at 0.45.

Conversely, VK Company Ltd saw a 0.48% drop or 0.65 points, settling at 136.15, while TATNEFT and Sberbank Rossii PJSC experienced declines of 0.21% and 0.07% respectively, ending at 629.20 and 287.08. The Moscow Stock Exchange saw 188 stocks rise, 51 fall, and 12 remain unchanged. The Russian Volatility Index (RVI), measuring the implied volatility of MOEX Russia Index options, was steady at 28.66, a three-month low.

Gold Futures for December delivery increased by 0.40% or 16.60 to $4,186.70 per troy ounce, while Crude oil for December delivery rose 3.95% or 3.87 to $99.02 per barrel. Meanwhile, the December Brent oil contract fell by 0.15% or 0.17 to $109.69 per barrel. USD/RUB decreased by 0.96% to 83.08, and EUR/RUB dropped by 0.80% to 93.35. The US Dollar Index Futures also saw a minor decline of 0.06% at 101.60.

Written by urgent.news from Investing.com's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at investing.com →

More in Finance & Markets

Where Will CRISPR Therapeutics Stock Be in 2030?

The company's expertise in gene editing could lead to more breakthroughs.

  • CRISPR Therapeutics stock declined 47% since mid-2021 while S&P 500 gained 73%.
  • Received approval for Casgevy, first CRISPR-based gene-editing therapy in 2023.
  • Promising pipeline candidates include LDL cholesterol reducer CTX310 and anticoagulant CTX611.

More from Sunday 18 October →